Avalo Therapeutics, Inc. Common Stock

Day range

$6.67 – $7.13

Open

$6.82

Prev close

$6.93

Volume

1.17M

Market cap

$371.66M

Shares out

53.63M

P/E

—

P/S

6299.25

P/B

0.83

P/FCF

—

ROE

-22.4%

ROA

-20.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentJun 23, 2026

  On June 23, 2026, the board of directors (the "Board") of Avalo Therapeutics, Inc. (the "Company") appointed Ron Philip to the Board, effective June 23, 2026. Mr. Philip will serve as a director until the Company's 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified. Mr. Philip will serve as a member of the Compensation Committee and Science, Development and Commercial Advisory Committee immediately upon his appointment.

• Investor presentationJun 16, 2026

  The Company has posted on its website an updated investor presentation (the "Investor Presentation"). The Investor Presentation will be used from time to time in meetings with investors.

• Preferred stock modificationJun 12, 2026

  On June 11, 2026, in connection with the Exchange, the Company filed a Certificate of Designation to its Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Designation"), with the Secretary of State of the State of Delaware for the purpose of designating the Series C-1 Preferred Stock. The purpose of the Exchange is to provide the investor with a class of preferred stock identical to the current Series C Preferred Stock other than the removal of the restriction applicable to the investor in the Series C Preferred Stock preventing the investor from increasing its beneficial ownership limit from 4.99% of the Company's common stock to 9.99% of the Company's common stock.

• Preliminary resultsMay 7, 2026

  As of March 31, 2026, the Company estimates that it had cash, cash equivalents and short-term investments of approximately $82.0 million. This financial data as of March 31, 2026 is preliminary and may change and is based on information available to management as of the date of the Prospectus Supplement.

• Clinical trial resultsMay 5, 2026

  On May 5, 2026, Avalo Therapeutics, Inc. (the "Company") issued a press release announcing positive topline results from its Phase 2 LOTUS trial evaluating the efficacy, safety and tolerability of abdakibart in patients with moderate to severe hidradenitis suppurativa.

Days to cover

8.8

Short interest

11.41M

Avg volume

1.3M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
  positiveGlobeNewswire Inc.· Jun 26, 2026
• Avalo Therapeutics Announces Pricing of $375 Million Public Offering
  positiveGlobeNewswire Inc.· May 5, 2026
• Avalo Therapeutics to Participate in Upcoming Investor Conferences
  neutralGlobeNewswire Inc.· Feb 4, 2026
• Hidradenitis Suppurativa Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 24+ Companies and 26+ Therapies | DelveInsight
  positiveGlobeNewswire Inc.· Oct 23, 2025
• Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
  positiveBenzinga· Sep 29, 2025